See All Slides - tctmd.com

Slides

Presentation THT 2024

New Endpoints and Experimental Designs for Devices for Chronic Heart Failure (Breakthrough)

Presenter: William T. Abraham

March 06, 2024

Presentation THT 2024

Counter Pulsation of the PA: Aria CV

Presenter: Jane A. Leopold

March 06, 2024

Presentation THT 2024

Multicenter Development and Validation of a Supervised Machine Learning Risk Model to Predict Right Ventricular Failure Following Mechanical Circulatory Support: The STOP-RVF Score

Presenter: Stavros G. Drakos

March 06, 2024

Presentation THT 2024

Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance

Presenter: Jeffrey Testani

March 06, 2024

Presentation THT 2024

Reclassification of PH Based with New Endo-Phenotypes

Presenter: Evelyn Miriam Horn

March 06, 2024

Presentation THT 2024

Catheters Are Over-Rated! Heparin as the Primary Option

Presenter: Sanjum S. Sethi

March 06, 2024

Presentation THT 2024

Inclusion Criteria and Endpoints for Trials of Devices to Treat ADHF

Presenter: Maria Rosa Costanzo

March 06, 2024

Presentation THT 2024

AI Assisted Identification of Super responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial

Presenter: Deya Alkhatib

March 06, 2024

Presentation THT 2024

Disaggregating Left Heart Disease-Pulmonary Hypertension

Presenter: Bradley A. Maron

March 06, 2024

Presentation THT 2024

Catheter Thrombectomy as the Primary Option

Presenter: Kenneth Rosenfield

March 06, 2024

Advertisement

Slides

New Endpoints and Experimental Designs for Devices for Chronic Heart Failure (Breakthrough)

Counter Pulsation of the PA: Aria CV

Multicenter Development and Validation of a Supervised Machine Learning Risk Model to Predict Right Ventricular Failure Following Mechanical Circulatory Support: The STOP-RVF Score

Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance

Reclassification of PH Based with New Endo-Phenotypes

Catheters Are Over-Rated! Heparin as the Primary Option

Inclusion Criteria and Endpoints for Trials of Devices to Treat ADHF

AI Assisted Identification of Super responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial

Disaggregating Left Heart Disease-Pulmonary Hypertension

Catheter Thrombectomy as the Primary Option

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content